Please login to the form below

Not currently logged in

Lucid Group promotes Clare Reynolds to newly created role

Reynolds initially joined Lucid in 2009 as business unit director

Lucid Group has promoted Clare Reynolds (pictured above) to director of business development and commercial integration.

Reynolds initially joined Lucid in 2009 as business unit director – since then, she has progressed through the ranks at the medcomms company, most recently working as senior managing partner.

In a statement, Lucid said Reynolds had played a 'key role' in developing new and existing clients for the company, leading to the promotion.

In her new role, Reynolds will aim to enhance Lucid's ability to improve health outcomes and also build on the company's strategic partnerships.

She will also lead the introduction of new capabilities into Lucid's teams to attract new clients, companies and candidates.

"By firmly engaging with this intent through our client partnerships, we lead with improving patient outcomes and build our business in the process," commented Reynolds.

"This new role creates the opportunity to more tangibly align the way we approach our client partnerships with our vision, and to expand our capabilities in a way that brings incremental value to our clients and the healthcare communities within which we work," she added.

Prior to Lucid, Reynolds served as marketing director, HIV International for Gilead Sciences.

Article by
Lucy Parsons

29th April 2021

From: Marketing


COVID-19 Updates and Daily News

Featured jobs


Add my company
Madmicrobe Studios - Medical Animation

MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...